Clearmind Medicine CMND 深 滬
等待開盤 11-04 09:30:00 美东时间
5.92
-0.220
-3.58%
華盛通- 最 高6.10
- 今 開5.81
- 成交量 4700股
- 最 低 5.43
- 昨 收 6.14
- 總市值 300.38万
- 52周最高 1272.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 5.25
- 委 比 25.00%
- 總股本 50.74万
- 歷史最高 585600.00
- 量 比 0.86
- 振 幅 10.91%
- 歷史最低 5.25
- 每 手 1
- 風險率 422.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Clearmind Medicine Completes Participant Recruitment For First Segment Of Part B Of Its Phase I/IIa Clinical Study Of CMND-100 To Treat Alcohol Use Disorder
Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind" or the "Company"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder ("AUD"), t...
10-27 20:23
Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial
Clearmind Medicine Inc. announced the completion of patient recruitment for the first segment of Part B of its Phase I/IIa clinical trial evaluating CMND-100 in patients with moderate-to-severe Alcohol Use Disorder (AUD). Part B marks the first clinical evaluation of CMND-100 in AUD patients, following successful completion of Part A in healthy volunteers. The trial is assessing safety, tolerability, pharmacokinetics, and early efficacy signals, ...
10-27 12:22
Clearmind Medicine's Charging Robotics Subsidiary Rolls Out Autonomous Vehicle Charging Platform
Clearmind Medicine Inc. (NASDAQ:CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation psychedelic, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announc...
10-12 19:56
Clearmind Medicine Publishes Patient Application In Japan For Its Compositions And Methods For Treating Dyskinesia
Clearmind Medicine Inc. (Nasdaq: CMND) (the "Company"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder ("AUD"), today announced t...
10-08 19:33
Clearmind Medicine Announces 1-For-8 Reverse Share Split, Effective October 5, 2026
learmind Medicine Inc. (the "Company") is announcing that it will effect a reverse share split of the Company’s common shares at the ratio of 1-for-8, such that each eight (8) common shares, no par value, shall be consolidated into one (1) common share, no par value. The first date when the Company’...
10-01 04:54
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
Clearmind Medicine Inc. participated in a historic FDA hearing on psychedelic drugs, with Mary-Elizabeth Gifford discussing patient access and insights from the company’s clinical trials at Yale and Johns Hopkins. Clearmind’s neuroplastogenic compounds, which eliminate hallucinogenic effects while retaining therapeutic benefits, may reduce the need for costly supervised dosing, offering a scalable treatment model. The company’s MEAI candidate, ta...
09-17 11:42
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
Clearmind Medicine Inc. announced the enrollment of the first AUD patients in its CMND-100 clinical trial, marking a significant milestone in its neuroplastogen-based treatment development.
09-11 12:00
Clearmind Medicine Inc. GAAP EPS of -$0.57
Clearmind Medicine Inc. press release (CMND): Q3 GAAP EPS of -$0.57. More on Clearmind Medicine Inc. Clearmind Medicine signs agreement to acquire 51% stake in Charging Robotics Financial information ...
09-11 04:19
Clearmind Medicine Stock Slides Friday: What's Happening?
Shares of Clearmind Medicine Inc. (NASDAQ:CMND) are trading lower Friday morning as investors digest news of the clinical-stage biotech company expanding beyond its core pharmaceutical focus to acquire a majority stake in an electric vehicle charging firm. Clearmind Medicine shares are sliding. What...
09-04 20:59
Clearmind Medicine signs agreement to acquire 51% stake in Charging Robotics
Clearmind Medicine (CMND) on Friday said it has entered into a definitive agreement to acquire a 51% stake in Charging Robotics, an EV wireless charging firm for automated parking and robotaxis. Under...
09-04 19:39
